Literature DB >> 11278732

Serine proteinase inhibitor 3 and murinoglobulin I are potent inhibitors of neuropsin in adult mouse brain.

K Kato1, T Kishi, T Kamachi, M Akisada, T Oka, R Midorikawa, K Takio, N Dohmae, P I Bird, J Sun, F Scott, Y Miyake, K Yamamoto, A Machida, T Tanaka, K Matsumoto, M Shibata, S Shiosaka.   

Abstract

Extracellular serine protease neuropsin (NP) is expressed in the forebrain limbic area of adult brain and is implicated in synaptic plasticity. We screened for endogenous NP inhibitors with recombinant NP (r-NP) from extracts of the hippocampus and the cerebral cortex in adult mouse brain. Two SDS-stable complexes were detected, and after their purification, peptide sequences were determined by amino acid sequencing and mass spectrometry, revealing that target molecules were serine proteinase inhibitor-3 (SPI3) and murinoglobulin I (MUG I). The addition of the recombinant SPI3 to r-NP resulted in an SDS-stable complex, and the complex formation followed bimolecular kinetics with an association rate constant of 3.4 +/- 0.22 x 10(6) M(-1) s(-1), showing that SPI3 was a slow, tight binding inhibitor of NP. In situ hybridization histochemistry showed that SPI3 mRNA was expressed in pyramidal neurons in the hippocampal CA1-CA3 subfields, as was NP mRNA. Alternatively, the addition of purified plasma MUG I to r-NP resulted in an SDS-stable complex, and MUG I inhibited degradation of fibronectin by r-NP to 24% at a r-NP/MUG I molar ratio of 1:2. Immunofluorescence histochemistry showed that MUG I localized in the hippocampal neurons. These findings indicate that SPI3 and MUG I serve to inactivate NP and control the level of NP in adult brain, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278732     DOI: 10.1074/jbc.M010725200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo.

Authors:  Hideki Tamura; Yasuyuki Ishikawa; Noriko Hino; Maoko Maeda; Shigeru Yoshida; Shinsuke Kaku; Sadao Shiosaka
Journal:  J Physiol       Date:  2005-11-24       Impact factor: 5.182

2.  Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus.

Authors:  Fernando J Salles; Sidney Strickland
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

3.  Amniotic fluid transcriptomics reflects novel disease mechanisms in fetuses with myelomeningocele.

Authors:  Tomo Tarui; Aimee Kim; Alan Flake; Lauren McClain; John D Stratigis; Inbar Fried; Rebecca Newman; Donna K Slonim; Diana W Bianchi
Journal:  Am J Obstet Gynecol       Date:  2017-07-20       Impact factor: 10.693

4.  Targeted disruption of SPI3/Serpinb6 does not result in developmental or growth defects, leukocyte dysfunction, or susceptibility to stroke.

Authors:  Katrina L Scarff; Kheng S Ung; Harshal Nandurkar; Peter J Crack; Catherina H Bird; Phillip I Bird
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 5.  Hox genes and their candidate downstream targets in the developing central nervous system.

Authors:  Z N Akin; A J Nazarali
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

6.  Involvement of acidic fibroblast growth factor in spinal cord injury repair processes revealed by a proteomics approach.

Authors:  Ming-Chu Tsai; Li-Fen Shen; Huai-Sheng Kuo; Henrich Cheng; Kin-Fu Chak
Journal:  Mol Cell Proteomics       Date:  2008-05-14       Impact factor: 5.911

Review 7.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

8.  Structural determinants of specificity and regulation of activity in the allosteric loop network of human KLK8/neuropsin.

Authors:  Mekdes Debela; Viktor Magdolen; Wolfgang Skala; Brigitta Elsässer; Eric L Schneider; Charles S Craik; Martin L Biniossek; Oliver Schilling; Wolfram Bode; Hans Brandstetter; Peter Goettig
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.